Abstract
The mitotic checkpoint is thought to be essential for ensuring accurate chromosome segregation by implementing mitotic delay in response to a spindle defect. To date, however, very little data has become available on the defects of the mitotic checkpoint in human cancer cells. In the present study, impaired mitotic checkpoint was found in four (44%) of nine human lung cancer cell lines. To our knowledge, this is the first demonstration of frequent impairment of the mitotic checkpoint in this leading cause of cancer deaths. As an initial step towards elucidation of the underlying mechanism, we further undertook a search for mutations in a key component of the mitotic checkpoint, known as hsMAD2, and its immediate downstream molecule, p55CDC. No such mutations were found, however, in either 21 lung cancer cell lines or 25 primary lung cancer cases, although we could identify silent polymorphisms and the transcribed and processed hsMAD2 pseudogene that was subsequently mapped at 14q21-q23. The present observations appear to warrant further investigations, such as search for alterations in other components, to better understand the molecular pathogenesis of this fatal disease, and warn against potential misinterpretation when performing mutational analyses for other cancer types based on cDNA templates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B. . 1998 Science 282: 1497–1501.
Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JKV, Markowitz SD, Kinzler KW and Vogelstein B. . 1998 Nature 392: 300–303.
Chen RH, Waters JC, Salmon ED and Murray AW. . 1996 Science 274: 242–246.
Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH and Reid BJ. . 1995 Science 267: 1353–1356.
Elledge SJ. . 1998 Science 279: 999–1000.
Gotoh K, Yatabe Y, Sugiura T, Takagi K, Ogawa M, Takahashi T, Takahashi T and Mitsudomi T. . 1999 Carcinogenesis (in press).
Gualberto A, Aldape K, Kozakiewicz K and Tlsty TD. . 1998 Proc. Natl. Acad. Sci. USA 95: 5166–5171.
He X, Patterson TE and Sazer S. . 1997 Proc. Natl. Acad. Sci. USA 94: 7965–7970.
Hibi K, Yamakawa K, Ueda R, Horio Y, Murata Y, Tamari M, Uchida K, Takahashi T, Nakamura Y and Takahashi T. . 1994 Oncogene 9: 611–619.
Hoyt MA, Totis L and Roberts BT. . 1991 Cell 66: 507–517.
Hwang LH, Lau LF, Smith DL, Mistrot CA, Hardwick KG, Hwang ES, Amon A and Murray AW. . 1998 Science 279: 1041–1044.
Kim SH, Lin DP, Matsumoto S, Kitazono A and Matsumoto T. . 1998 Science 279: 1045–1047.
Kondo M, Suzuki H, Ueda R, Osada H, Takagi K, Takahashi T and Takahashi T. . 1995 Oncogene 10: 1193–1198.
Krishnan R, Goodman B, Jin DY, Jeang KT, Collins C, Stetten G and Spencer F. . 1998 Genomics 49: 475–478.
Lanni JS and Jacks T. . 1998 Mol. Cell. Biol. 18: 1055–1064.
Lengauer C, Kinzler KW and Vogelstein B. . 1997 Nature 386: 623–627.
Li R and Murray AW. . 1991 Cell 66: 519–531.
Li Y and Benezra R. . 1996 Science 274: 246–248.
Minna JD, Sekido Y, Fong KM and Gazdar AF. . 1997 In: Cancer Principles & Practice of Oncology, 5th edn, vol. 1. De Vita Jr VT, Hellman S and Rosenberg SA (eds).. Lippincott-Raven: Philadelphia. pp. 849–857.
Paulovich AG, Toczyski DP and Hartwell LH. . 1997 Cell 88: 315–321.
Rudner AD and Murray AW. . 1996 Curr. Opin. Cell Biol. 8: 773–780.
Statistics and Information Department. . 1998 In: Vital Statistics of Japan 1996, Vol. 3. Ministry of Health and Welfare: Tokyo. pp. 384–411.
Takahashi T, Ueda R, Song X, Nishida K, Shinzato M, Namikawa R, Ariyoshi Y, Ota K, Kato K, Nagatsu T, Imaizumi M, Abe T and Takahashi T. . 1986 Cancer Res. 46: 4770–4775.
Takahashi T, Nau M, Chiba I, Birrer M, Rosenberg R, Vinocour M, Levitt M, Pass H, Gazdar A and Minna J. . 1989 Science 246: 491–494.
Testa JR. . 1996 In: Lung Cancer: Principles and Practice. Pass HI, Mitchell JB, Johnson DH and Turrisi AT (eds).. Lippincott-Raven: Philadelphia. pp. 55–71.
Weinstein J, Jacobsen FW, Hsu-Chen J, Wu T and Baum LG. . 1994 Mol. Cell. Biol. 14: 3350–3363.
Acknowledgements
We would like to thank R Ishida for his helpful suggestions and stimulating discussion. This work was supported in part by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science, Sport and Culture, Japan and a Grant-in-Aid for the Second Term Comprehensive Ten-Year Strategy for Cancer Control.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takahashi, T., Haruki, N., Nomoto, S. et al. Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers. Oncogene 18, 4295–4300 (1999). https://doi.org/10.1038/sj.onc.1202807
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202807
Keywords
This article is cited by
-
Genetic instability: tipping the balance
Oncogene (2013)
-
Increased expression of Mitotic Arrest Deficient-Like 1 (MAD1L1) is associated with poor prognosis and insensitive to Taxol treatment in breast cancer
Breast Cancer Research and Treatment (2013)
-
Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression
Journal of Hematology & Oncology (2012)
-
The spindle assembly checkpoint: perspectives in tumorigenesis and cancer therapy
Frontiers in Biology (2011)
-
Effect of Mad2 on paclitaxel-induced cell death in ovarian cancer cells
Journal of Huazhong University of Science and Technology [Medical Sciences] (2010)